XNW-3009 is under clinical development by Evopoint Bioscience and currently in Phase II for Hyperuricemia. According to GlobalData, Phase II drugs for Hyperuricemia have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XNW-3009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XNW-3009 overview
XNW-3009 is under development for the treatment of gouty arthritis (Gout) and hyperuricemia. It is administered via oral route. The drug candidate acts by targeting human uric acid transporter 1 (hURAT1).
Evopoint Bioscience overview
Evopoint Bioscience, formerly Suzhou Sinovent Pharmaceuticals, is a biopharmaceutical company that involved in development of therapeutics for oncology, autoimmunity, and infectious diseases. The company is headquartered in Suzhou, Jiangsu, China.
For a complete picture of XNW-3009’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#XNW3009 #Evopoint #Bioscience #Hyperuricemia #Likelihood #Approval
